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Background: Gastro-oesophageal adenocarcinomas rarely metastasize to the central nervous system (CNS). The role of the
human epidermal growth factor receptor 2 (HER2) in patients with these cancers and CNS involvement is presently unknown.
Patients and Methods: A multicentre registry was established to collect data from patients with gastro-oesophageal
adenocarcinomas and CNS involvement both retrospectively and prospectively. Inclusion in the study required a predefined
clinical data set, a central neuro-radiological or histopathological confirmation of metastatic CNS involvement and central
assessment of HER2 by immunohistochemistry (IHC) and in situ hybridisation (ISH). In addition, expression of E-cadherin and DNA
mismatch repair (MMR) proteins were assessed by IHC.
Results: One hundred patients fulfilled the inclusion criteria. The population’s median age was 59 years (interquartile range:
54–68), of which 85 (85%) were male. Twenty-five patients were of Asian and 75 of Caucasian origin. HER2 status was positive in
36% (95% CI: 26.6–46.2) of cases. Median time from initial diagnosis to the development of brain metastases (BMets) or
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leptomeningeal carcinomatosis (LC) was 9.9 months (95% CI: 8.5–15.0). Median overall survival from diagnosis was 16.9 months
(95% CI: 14.0–20.7) and was not related to the HER2 status. E-cadherin loss was observed in 9% of cases and loss of expression in at
least one DNA MMR proteins in 6%.
Conclusions: The proportion of a positive HER2 status in patients with gastro-oesophageal adenocarcinoma and CNS
involvement was higher than expected. The impact of anti-HER2 therapies should be studied prospectively.
Adenocarcinoma of the stomach, including the gastro-oesophageal
junction, is the fifth most common cancer in the world, and is
predominantly diagnosed in Eastern Asia. Peak onset of the disease
is between 60 and 80 years of age and age-standardised incidence
rates of gastro-oesophageal adenocarcinoma are twice as high in
males than in females. There is significant geographic variation
with age-standardised incidence rates ranging from 3.3 in Western
Africa to 35.4 in Eastern Asia for men, and from 2.6 in Western
Africa to 13.8 in Eastern Asia for women (http://ci5.iarc.fr).
A better clinical outcome has been reported for Asians, females and
young age (Al-Refaie et al, 2008; Kunz et al, 2012).
Metastases from gastro-oesophageal adenocarcinoma primarily
involve the peritoneal cavity, liver and lymph nodes (Maehara et al,
2000; D’Angelica et al, 2004). Metastases to the brain are rare
(York et al, 1999; Go et al, 2011) and occur in less than 5% of
patients with adenocarcinoma of the upper gastrointestinal tract
(Wadhwa et al, 2013; Blay et al, 2015).
The product of the HER2 gene, a member of the epidermal
growth factor (EGF) receptor family, is overexpressed and the
gene is amplified in 10–22% of patients with gastro-oesophageal
adenocarcinoma, both in Asian and in Caucasian patients. The
variability in HER2 positivity reported in different studies can
partially be explained by intratumoural heterogeneity, insufficient
tissue sampling or inconsistent interpretation criteria (Gravalos
and Jimeno, 2008; Hofmann et al, 2008; Bang et al, 2010; Grabsch
et al, 2010; Janjigian et al, 2012; Warneke et al, 2013a,b;
Van Cutsem et al, 2014).
In gastric cancer, the ToGa trial has recently established HER2
as a predictive marker for response to the monoclonal anti-HER2
antibody trastuzumab. This trial did not include patients with
brain metastases (BMets) (Bang et al, 2010).
Few studies have analysed the clinical significance of HER2 in
patients with gastro-oesophageal adenocarcinoma and CNS
involvement. In a retrospective cohort of 140 patients with
oesophageal cancer, 9 patients developed BMets—5 of them were
HER2 positive based on immunohistochemistry (IHC) (Abu
Hejleh et al, 2012). In a small series of 20 patients with BMets of
gastro-oesophageal adenocarcinoma, three were HER2 positive
based on IHC and fluorescence in situ hybridisation (FISH)
analysis (Preusser et al, 2013). Since patients with HER2 positive
breast cancer were reported to develop BMets more frequently and
more rapidly than patients with HER2 negative cancers (Pestalozzi
et al, 2006; Musolino et al, 2011), we aimed to establish the
frequency of HER2 positivity in patients with brain metastases
from gastro-oesophageal adenocarcinoma.
E-cadherin (encoded by the CDH1 gene), a transmembrane
glycoprotein involved in maintaining cell–cell contact, has recently
been implicated in mediating BMets. Studies examining BMets
tissue from lung cancer (Kafka et al, 2014) have reported a frequent
loss of E-cadherin expression, suggesting a potential role in BMets
development. Since both, loss of E-cadherin expression and
mutation (deletion), have been associated with worse prognosis
in gastric cancer (Uchikado et al, 2011; Corso et al, 2013), we also
wanted to investigate the relationship between E-cadherin status
and its relationship with clinicopathological variables in our study
population.
Microsatellite instability (MSI), an alteration caused by genetic
and epigenetic inactivation of DNA mismatch repair (MMR) genes
is usually related to a loss of function of the MMR enzyme system.
In sporadic gastric cancer, MMR deficiency occurs in about 10% of
cases and has been linked to a more favourable clinical course
(Lee et al, 2002; Warneke et al, 2013a,b; Choi et al, 2014). We
therefore anticipated MMR deficiency to be a rare event in our
study population.
To investigate the status of HER2, E-cadherin, and MSI we
established a registry of European and Asian patients with gastro-
oesophageal adenocarcinomas who had developed metastases to
the brain and/or to the leptomeninges.
PATIENTS AND METHODS
Eligible patients met the following criteria: Histologically
confirmed adenocarcinoma of the stomach or oesophagus;
availability of a clinical data set as defined in the study protocol;
central nervous system (CNS) involvement confirmed by central
neuro-radiological or histopathological review (cytology, surgical
pathology, or autopsy); in the absence of brain images, the medical
reports had to demonstrate conclusive evidence of BMets;
availability of tumour tissue (from primary and/or from CNS or
visceral metastases) for histological review, assessment of HER2
status, expression of E-cadherin and DNA MMR proteins.
The ethics committee of the Canton of Zurich, Switzerland
(KEK-ZH-NR: 201 0-0445) and the ethics committees of all
collaborating centres approved the study, which is registered on
www.ClinicalTrials.gov, NCT01456455.
The local investigators collected clinical and follow-up data
from medical records either from hospital records or from the
patients’ general practitioners. Written informed consent was
obtained from all patients alive at the time of their inclusion into
the study.
Neuroradiology. The review was performed by a board certified
neuroradiologist specialised in neuro-oncology (BS). The patient’s
neuro-imaging studies, including MRI and CT scans, were
analysed on a state of the art PACS (Picture and Archiving
Communication System) and categorized according to the
presence of CNS metastases as a single lesion, multiple lesions
(p3 or 43), and/or as leptomeningeal carcinomatosis (LC).
Metastases to the CNS were defined as one or multiple contrast
enhancing lesions in the brain, in the lepto- or pachymeninges, or
in the ependymal lining of the ventricular system. MRIs were
analysed based on standardized sequences that is, axial T1, T2, and
FLAIR-weighted series with a slice thickness of 4mm and 3D
contrast-enhanced sequence with 1mm slice thickness recon-
structed in three planes. CT scans included non-contrast and
contrast exams with 1mm slice thickness and with reconstruction
of the contrast-enhanced series performed in three planes.
Histopathological assessment. Paraffin blocks and/or unstained
slides with sufficient tumour tissue were submitted for central
pathology review to the Institute of Surgical Pathology, University
Hospital Zurich, Switzerland, where the pathological diagnosis
(e.g., the presence of adenocarcinoma) was confirmed either based
on the review of glass slides or based on the review of digital slides
by the study’s principal pathologist (ZV).
HER2 and brain metastases from gastro-oesophageal cancer BRITISH JOURNAL OF CANCER
www.bjcancer.com |DOI:10.1038/bjc.2015.279 717
Histological subtypes and grade of differentiation were deter-
mined according to the Laure´n (1965) and the WHO classification
(Bosman et al, 2010). Adenocarcinomas were categorised as
intestinal, diffuse, or mixed type. Adenocarcinomas with signet-
ring cells were classified as diffuse type. All diffuse type cancers
were graded as poorly differentiated (G3), whereas intestinal type
cancers were graded as well (G1), moderate (G2), or poorly (G3)
differentiated.
HER2 immunohistochemistry. HER2 protein was assessed using
the FDA-approved ready-to-use antibody, PATHWAY anti-HER2/
neu clone 4B5 (Ventana Medical Systems, Basel, Switzerland). The
immunohistochemical procedure was carried out using the Leica
Bond autostainer (Leica Biosystems, Nunningen, Switzerland) or
the Ventana Bench Mark Ultra autostainer.
Scoring was performed in accordance with the guidelines of the
ToGA trial (Bang et al, 2010) and the corresponding literature
(Ru¨schoff et al, 2012).
HER2 fluorescence or silver enhanced in situ hybridisation. All
cases tested in Zurich, except for patient 100, and all cases from the
Netherlands Cancer Institute (NCI), patients 87–99, were tested
using silver enhanced in situ hybridisation (SISH). Patient 100 was
analysed using FISH.
SISH HER2 analysis. HER2 copy number status determined with
SISH was performed using a dual probe (INFORM HER2 Dual ISH
assay, Ventana Medical Systems, Tucson, AZ, USA, catalog Nr:
780-4332) containing the HER2 region (17q11.2–q12, directly
labelled with black) and the centromeric region of chromosome 17
(17p11.1–q11.1, directly labelled with red). The signals were
detected with the UltraView SISH detection kit and the UltraView
red ISH detection kit as per instructions by the manufacturer. The
in situ hybridisation procedure was carried out using the Ventana
Benchmark autostainer according to the manufacturer
recommendation.
At the NCI, ISH Protease 3 (cat. #5273331001, Ventana Medical
Systems), INFORM HER2 DNA Probe (cat. #5273439001, Ventana
Medical Systems), and Rabbit anti-DNP (cat. #5273447001,
Ventana Medical Systems) were used. Bound probe was visualised
using silver deposition (ultraVIEW SISH Detection Kit, Ventana
Medical Systems) followed by haematoxylin counterstain.
Scoring of SISH signals followed the guidelines established in
the ToGA trial (Bang et al, 2010).
FISH HER2 analysis (case 100). Fluorescence in situ hybridisa-
tion was used to establish the HER2 copy number status in case 100
as described previously (Varga et al, 2012). The FISH scoring was
performed in analogy to the scoring applied for SISH.
In summary, HER2 positive tumours were defined as IHC score
3þ or ISH amplified (FISH or SISH) in at least one probe
(primary tumour and/or metastastic lesion).
E-cadherin immunohistochemistry. E-cadherin IHC was per-
formed using either clone EP700Y (Cell Marque, dilution 1 : 200)
and the Ventana Benchmark autostainer or clone NCH-38
(DAKO; Cat. #M3612, dilution 1 : 50) followed by the UltraView
Universal DAB Detection Kit (Ventana Medical Systems).
Any membranous immunoreactivity, irrespective of the number
of cells or the intensity, was scored as positive. The absence of
membranous immunoreactivity or the presence of cytoplasmic
stain only was scored as negative.
DNA MMR proteins IHC. Immunohistochemistry for MSH2
(clone 25D12, Novocastra (Biosystems Switzerland, Muttenz,
Switzerland), dilution 1 : 100; or Clone G219-1129, Roche Ventana
Medical Systems, ready-to-use), MSH-6 (clone 44, Becton Dick-
inson, Allschwil, Switzerland, dilution 1 : 500; or Clone EP49,
Epitomics (LabForce, Nunningen, Switzerland), dilution 1 : 50),
MLH1 (clone G168-15, Becton Dickinson, dilution 1 : 100; or clone
M1, Roche Ventana Medical Systems, ready-to-use) and PMS2
(clone A16-4, Becton Dickinson, dilution 1 : 300; or Clone
EPR3947, Roche Ventana Medical Systems, ready-to-use) was
performed using the Ventana Benchmark system or using the
OptiView DAB Detection Kit (Ventana Medical Systems) followed
by counterstaining with haematoxylin.
Any nuclear staining in the tumour cells was considered as
‘positive’. Complete absence of immunoreactivity in the presence of
a positive internal control (lymphocytes) was scored as ‘negative’.
Statistics. Descriptive statistics were calculated for the variables of
interest, and stratified by subgroups of HER2 status (positive vs
negative) and ethnicity (Asian vs Caucasian). Overall survival was
calculated from initial diagnosis to death or last follow-up. Survival
from BMets was calculated from diagnosis of BMets to death or
last follow-up. Time to BMets was calculated from initial diagnosis
to the diagnosis of BMets. We obtained median survival times and
their 95% confidence intervals using the Kaplan–Meier method.
Results are presented for all patients as well as for the subgroups by
HER2 status. All analyses were conducted with R (R Core Team,
2015). A P-value of 0.05 was set as statistically significant.
RESULTS
Patients. A total of 129 patients were included in the registry
from 2011 to 2013. Of these, 100 fulfilled the inclusion criteria
for this study (see Appendix).
Twenty-nine registered patients were excluded because (i) there
was no tissue available for confirmation of the diagnosis and
further analysis (8), (ii) squamous cell histology (7), (iii) lack of
clinical data (11), or (iv) the absence of radiologically or
histologically confirmed BMets or LC (3) (Figure 1).
The median age of the included study patients was 59 years
(interquartile range 54–68 years) and 85 (85%) were males, 25
(25%) were of Asian ethnicity and 75 (75%) were Caucasian. Forty-
five (45%) tumours were located at the cardia and 53 (53%) were
classified as ‘non-cardia’ cancers, of which 32 (32%) were located
in the lower oesophagus (in two cases the tumour localisation was
unknown). In 21 (21%) patients BMets were diagnosed synchro-
nously and in 79 (79%) metachronously.
CNS involvement. Central nervous system involvement was
confirmed in 90 patients by diagnostic imaging or by CNS
histology or cytology. For 10 patients, MRI or CT scans were not
available for review, however, the provided patient medical reports
demonstrated conclusive evidence of BMets. Three patients had to
be excluded from further analysis due to diagnostic errors (cerebral
embolic infarction in two patients and cerebral hemorrhage in
one).
CNS involvement was as follows: BMets (n¼ 74, 74%), LC alone
(n¼ 15, 15%), BMets and LC (n¼ 11, 11%). Extracerebral
metastases were present in 80% of patients (in 6% no information
was available). Four of the thirty-six patients with HER2 positive
No radiological or
histological confirmation
of brain metastases
n=3
Clinical data
incomplete
n=11
Central
pathology
review
Cases registered
n= 129
Cases included in analyses
n=100
No tissue available
n=8
Squamous cell
carcinoma n=7
Figure 1. Consort diagram.
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tumours received trastuzumab for metastatic disease. Patient
characteristics are summarised in Table 1.
Histopathological review. Tissue was available from the primary
tumour in 75% of all patients; in 13% of the cases, primary tumour
tissue and matched tissue from at least one distant metastasis could
be analysed (eight metastases from the brain and five metastases
from lung, lymph nodes and/or liver). In 23 cases, tissue from one
or more metastatic sites was available and in two tumour samples
(2%) no precise anatomical location was possible.
Sixty percent of the cancers were intestinal-type, 24% diffuse-
type, and 12% were classified as mixed-type. Four percent were
adenosquamous carcinomas. Twenty-five percent were moderately
differentiated (G2) and 75% were poorly differentiated (G3)
(Table 2).
HER2 status. Thirty-six (36%) of the cancers were HER2 positive
either in the primary tumour or in a metastatic lesion. In 11 cases,
the HER2 status was concordant between the primary tumour and
matched metastases. In two cases, the primary tumour was HER2
negative and the matched visceral metastases were HER2 positive.
The median time from initial diagnosis to the development of
metachronous BMets or LC was 9.9 months (95% CI: 8.5–15.1).
Patients with HER2 positive primaries developed BMets/LC within
a shorter time than patients with HER2 negative primaries (8.9
months, 95% CI: 4.3–14.7 vs 12.7 months, 95% CI: 8.8–17.2,
log-rank P¼ 0.157, not significant). The median overall survival of
all patients was 16.9 months (95% CI: 14.4–20.7); there was no
significant difference in survival between patients with HER2
positive tumours (17.4 months, 95% CI: 12.1–26.2) and those with
HER2 negative tumours (16.4 months, 95% CI: 14.1–21.0). Median
survival for patients with synchronous BMets (n¼ 21) was 5.2
months (95% CI: 3.5–16.9) whereas for metachronous BMets
(n¼ 79) median survival reached 19.0 months (95% CI: 16.4–26.2).
The median survival from diagnosis of CNS involvement of all
patients was 3.4 months (95% CI: 2.3–4.7); there was no significant
difference in survival between patients with HER2 positive
tumours (4.2 months, 95% CI 3.4–7.4) and HER2 negative
tumours (2.3 months, 95% CI 1.8–4.7) (Table 3).
E-cadherin status. E-cadherin data were available for 98 (98%)
cases. Nine (9%) demonstrated a complete loss of E-cadherin
immunostaining. There was no discrepancy between matched
tissue pairs. Outcome between E-cadherin positive and E-cadherin
negative patients was identical.
Expression of DNA MMR proteins. Expression of DNA MMR
proteins (MLH1, MSH2, MSH6, and PMS2) was assessed in 99 of
100 cases. Loss of expression of at least one of the proteins was seen
in 6%. MLH1 and PMS2 were absent in four cases. MLH1, PMS2,
and MSH6 were absent in two cases. Loss of MSH2 was not
observed. One of 12 matched tissue pairs showed loss of MLH1
and PMS2 in the cerebral metastasis but not in the corresponding
extracerebral tumour, all other pairs showed concordance. There
was no difference in outcome between MMR proficient and MMR
deficient patients.
Table 1. Patients characteristics
Total Caucasian Asian
Patients (n) 100 75 25
Age (years) (interquartile range) 59 (54–68) 60 (53–67) 58 (55–68)
Male/female 85/15 66/9 19/6
Tumour location
Non-cardia (including oesophagus) 53/98 35/73 18/25
Cardia 45/98 38/73 7/25
Not known 2 2 0
Primary tumour
Resected 41 27 14
Non- resected 50 43 7
Not known 9 5 4
CNS involvement
BMets 74 56 18
LC 15 12 3
Both 11 7 4
BMets
Synchronous 21/100 19/75 2/25
Metachronous 79/100 56/75 23/25
Extracerebral metastases
Present 80 61 19
Absent 14 13 1
Not known 6 1 5
RT to the brain 69 50 19
Abbreviations: BMets¼brain metastases; CNS¼ central nervous system; LC¼ leptomeningeal
carcinomatosis; n¼ numbers; RT¼ radiation therapy.
Table 2. Pathological characteristics
Total Caucasian Asian
Laure´n classification
Intestinal 60 48 12
Diffuse 24 16 8
Mixed 12 7 5
Adenosquamous 4 4 0
WHO grading
2 25/100 21/75 4/25
3 75/100 54/75 21/25
HER2 score (IHC and ISH)
Positive 36/100 28/75 8/25
Negative 64/100 47/75 17/25
MMR IHC
Deficient 93 70 23
Proficient 6 4 2
NA 1 1 0
E-Cadherin IHC
Present 89 67 22
Loss 9 7 2
NA 2 1 1
Abbreviations: HER2¼human epidermal growth factor receptor 2; IHC¼ immunohistochemistry;
ISH¼ in situ hybridisation; MMR¼mismatch repair proteins; NA¼not available; WHO¼World
Health Organisation. Laure´n classification: Laure´n (1965) and WHO grading: Bosman et al (2010).
Table 3. Clinical outcome and HER2 status
n (%) All
HER2
positive HER2 negative
100 (100) 36 (36) 64 (64)
Overall survival (months)
Median (95% CI) 16.9 (14.4;20.7) 17.4 (12.1;26.2) 16.4 (14.1; 21.0)
P¼NS
Survival from Bmets (months)
Median (95% CI) 3.38 (2.30;4.72) 4.16 (3.4;7.4) 2.30 (1.8;4.7)
P¼NS
Time to Bmets (months)
Median (95% CI) 9.93 (8.5;15.05) 8.92 (4.30;14.7) 12.7 (8.8;17.2)
P¼NS
Abbreviations: BMets¼brain metastases; CI¼ confidence interval; HER2¼ human epider-
mal growth factor receptor 2; IHC¼ immunohistochemistry; ISH¼ in situ hybridisation;
n¼ number; P¼NS P-value not significant. HER2 assessed with IHC and ISH methods.
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DISCUSSION
In the present study, we investigated the frequency of HER2
positivity, E-cadherin status, and DNA MMR protein expression
and their relationship with patient outcome in a large cohort
of patients with CNS metastases of gastro-oesophageal
adenocarcinomas. Brain metastases from upper GI cancer are
very rare; therefore, the number of patients collected within our
registry is substantial and unlikely to be reproduced in a
prospective trial.
In our study cohort of 100 patients, 36% had a HER2 positive
tumour. This incidence is higher than the reported proportion of
HER2 positivity in gastro-oesophageal adenocarcinoma (Gravalos
and Jimeno, 2008; Hofmann et al, 2008; Bang et al, 2010; Grabsch
et al, 2010; Janjigian et al, 2012; Warneke et al, 2013a,b; Van
Cutsem et al, 2014). Whether our findings suggest a propensity to
develop CNS metastases in this patient subgroup or rather reflects
a group of patients who lived long enough to develop BMets
remains to be investigated.
In cases where tissue was available from the primary tumour
and matched metastases (n¼ 13), the HER2 status was
concordant except for two cases, which could reflect spatial
intratumour heterogeneity (Bozzetti et al, 2011; Shibata
et al, 2014).
Twenty-six percent of our patients had leptomeningeal
carcinomatosis (LC), a disease manifestation that is even rarer
than brain metastases. In a large series of gastric adenocarcinoma,
LC occurred in 8 of 5618 patients with gastric (0.15%) and 7 of
4361 (0.16%) with oesophageal adenocarcinoma (Giglio et al,
2005). In our cohort, LC was not related to HER2 status.
Median survival of all patients was longer than expected for
patients with advanced disease. While we did not see any
relationship between HER2 status and survival, our cohort of
virtually trastuzumab-naı¨ve patients with HER2 positive cancers
seems to develop BMets more rapidly than patients with HER2
negative cancers, although the difference was not statistically
significant. Similar findings have been reported for breast cancer
(Musolino et al, 2011). Given the limited number of patients, our
observation will need to be confirmed.
The expression of E-cadherin and DNA MMR proteins was
similar between primary tumours and CNS metastases and did not
influence the clinical course of the disease.
Even though this is the largest cohort reported to date, 100
evaluable patients with gastro-oesophageal adenocarcinomas and
CNS involvement are still a relatively small number. A substantial
part of the analyses was performed retrospectively and may thus be
subject to bias. Some clinical data such as performance status, a
major prognostic factor for patients with brain metastases
(Sperduto et al, 2012), were not available for the retrospective
part of the study. Furthermore there is no matched control group
without BMets, thus we had to compare our results with data from
the literature.
All the same, our collaborative study has several important
strengths: centralised HER2 status assessment, central histopathol-
ogy review, and central review of clinical data reduced
technical sources of variation. Centralised assessment of the
cranial imaging increased the likelihood that CNS involvement
was accurately diagnosed. Finally, representation of Caucasian
and Asian patients enhances the generalisability of our study
findings.
In conclusion, we could show that HER2 is frequently
overexpressed and amplified in patients with gastro-oesophageal
adenocarcinomas and CNS involvement. HER2-targeted
therapies may favourably alter the prognosis of these patients
and may prolong the time to involvement of the brain and the
meninges.
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APPENDIX
The following cancer centres contributed to the study: The
Department of Oncology and Institute of Surgical Pathology,
University Hospital Zurich, Switzerland (n¼ 12); Pathology
Section, National Cancer Centre, Tokyo, Japan (n¼ 25);
The Department of Oncology and Institute of Pathology,
Cantonal Hospital St Gallen, Switzerland (n¼ 26); The
Department of Radiation Oncology, Cantonal Hospital of Valais,
Sion, Switzerland (n¼ 10); The Department of Radiation
Oncology and Institute of Pathology, Cantonal Hospital Luzern,
Switzerland (n¼ 8); The Netherlands Cancer Institute, The
Netherlands (n¼ 13); and three further centres in Switzerland
(n¼ 6).
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